En
Da
Fr
De
Sv
Deal History
About us
The Company
Team
Offices
Globalscope
Newsletter
Services
Corporate Finance
Debt Advisory
Equity Research
Growth Equity Financing
IPO Strategy & Preparation
Industries
Business Services
Consumer & Internet
Industrial Technology
Life Science
Software & TMT
Energy & Infrastructure
Research
Equity Research
Macro and Markets
Career
Events
Insights
News
Company News
Deal News
In the Media
Contact
Newsletter
En
Da
Fr
De
Sv
Main menu button
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Team
Deals
Contact
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Team
Deals
Contact
News
All
Abera Bioscience
Adventure Box
Adverty
All for One Group
ALM Equity
Alzecure Pharma
Arctic Minerals
Artificial Solutions
Biosergen
Candles Scandinavia
Carlsquare
CellaVision
CSAM Health Group
DanCann Pharma
Ecoclime
Elicera Therapeutics
Enrad
Frequentis
FRISQ
Future Gaming
GHP Specialty Care
GIAB
H&D Wireless
Hanza
Herantis Pharma
InCoax
Kancera
Medclair Invest
Midsummer
Mindark PE
Modus Therapeutics
Moninvent
NeoDynamics
Nischer Properties
Nosa Plugs
Observit
Orion Corporation
Pharmiva
Raytelligence
Risk Intelligence
SBB i Norden
Sensec
Spotlight Group
Svenska Aerogel
Thinc Jetty
Viva Wine Group
Ytrade Group
Zazz Energy
Zinzino
All
Company News
Deal News
Equity Research
Events
In the Media
Insights
Macro and Markets
17 May 2024
Equity research Nosa Plugs Q1, 2024: Tepid Q1 and updated company strategy
Equity Research
Nosa Plugs
16 May 2024
Equity Research Ecoclime Q1 2024: A weak quarter but continued growth for Evertherm
Equity Research
Ecoclime
16 May 2024
Equity Research GIAB Q1 2024: Slightly higher sales, but new savings needed
Equity Research
GIAB
16 May 2024
Equity research Viva Wine Group, Q1 2024: Profitability above our expectations despite soft top-line
Equity Research
Viva Wine Group
15 May 2024
Equity research HANZA Q1, 2024: Temporarily in a lower orbit
Equity Research
Hanza
15 May 2024
Carlsquare weekly market letter: Interest rates at a crossroads - will affect the whole market
Equity Research
Carlsquare
10 May 2024
Equity Research InCoax, Q1 2024: Strong start to 2024
Equity Research
InCoax
08 May 2024
Equity Research Svenska Aerogel, Q1 2024: Streamlining to reduce costs
Equity Research
Svenska Aerogel
08 May 2024
Carlsquare weekly market letter: Sell in May and stay away?
Equity Research
Carlsquare
07 May 2024
First Impression InCoax Q1 2024: Much better sales and results than expected
Equity Research
InCoax
07 May 2024
Equity research HANZA: First impression Q1 2024
Equity Research
Hanza
03 May 2024
Equity Research Svenska Aerogel, Q1 2024: Increasing effectivity and pilot order from key client
Equity Research
Svenska Aerogel
02 May 2024
Equity Research Enrad, Q1 2024: Better than expected start to 2024
Equity Research
Enrad
02 May 2024
Equity research Viva Wine Group, Q1 2024: Solid growth but at modest margins
Equity Research
Viva Wine Group
30 Apr 2024
Equity research, HANZA: Preview Q1 2024
Equity Research
Hanza
29 Apr 2024
Equity research Artificial Solutions: Outstanding NRR signals high value added and effectiveness
Equity Research
Artificial Solutions
26 Apr 2024
Equity Research Enrad, Q1 2024: Sales higher than expected
Equity Research
Enrad
25 Apr 2024
Preview ALM Equity Q1 2024: New residential profits to be made
Equity Research
ALM Equity
24 Apr 2024
Carlsquare weekly market letter: Time for the Magnificent Seven to set the tone
Equity Research
Carlsquare
17 Apr 2024
Carlsquare weekly market letter: Time to find shelter
Equity Research
Carlsquare
1
2
3
…
50